Angiopoietin/Tie2 Dysbalance Is Associated with Acute Kidney Injury after Cardiac Surgery Assisted by Cardiopulmonary Bypass

Rianne M. Jongman1,2,3, Jan van Klarenbosch4, Grietje Molema2, Jan G. Zijlstra3, Adrianus J. de Vries1☯, Matijs van Meurs2,3☯*

1 Department of Anesthesiology, University Medical Center Groningen, Groningen, the Netherlands, 2 Department of Pathology and Medical Biology, Medical Biology Section, University Medical Center Groningen, Groningen, the Netherlands, 3 Department of Critical Care, University Medical Center Groningen, Groningen, the Netherlands, 4 Department of Anesthesiology, University Medical Center Utrecht, Utrecht, the Netherlands

☯ These authors contributed equally to this work.
* m.van.meurs@umcg.nl

Abstract

Introduction

The pathophysiology of acute kidney injury (AKI) after cardiac surgery is not completely understood. Recent evidence suggests a pivotal role for the endothelium in AKI. In experimental models of AKI, the endothelial specific receptor Tie2 with its ligands Angiopoietin (Ang) 1 and Ang2 are deranged. This study investigates their status after cardiac surgery, and a possible relation between angiopoietins and AKI.

Methods

From a cohort of 541 patients that underwent cardiac surgery, blood and urine was collected at 5 predefined time points. From this cohort we identified 21 patients who had at least 50% post-operative serum creatinine increase (AKI). We constructed a control group (n = 21) using propensity matching. Systemic levels of Ang1, Ang2, and sTie2 were measured in plasma and the AKI markers albumin, kidney injury molecule-1 (KIM-1) and N-acetyl-beta-D-glucosaminidase (NAG) were measured in the urine.

Results

Ang2 plasma levels increased over time in AKI (from 4.2 to 11.6 ng/ml) and control patients (from 3.0 to 6.7 ng/ml). Ang2 levels increased 1.7-fold more in patients who developed AKI after cardiac surgery compared to matched control patients. Plasma levels of sTie2 decreased 1.6-fold and Ang1 decreased 3-fold over time in both groups, but were not different between AKI and controls (Ang1 P = 0.583 and sTie2 P = 0.679). Moreover, we found a positive correlation between plasma levels of Ang2 and urinary levels of NAG.
Conclusions

The endothelial Ang/Tie2 system is in dysbalance in patients that develop AKI after cardiac surgery compared to matched control patients.

Introduction

Acute kidney injury (AKI) is a major complication after cardiac surgery and is correlated with an increase in post-operative mortality [1]. The incidence of AKI after cardiac surgery varies ranging from 14–50% depending on the definition used [2]. Renal replacement therapy is necessary in about 3% of the patients with post-operative AKI [2]. Even if kidney function normalizes after the initial hospital stay, AKI is still correlated with long-term mortality and morbidity [3]. Understanding the pathophysiological mechanism of AKI is necessary to intervene in the development of AKI.

There is increasing evidence that the renal endothelium plays a crucial role in AKI development, by expressing endothelial adhesion molecules leading to leukocyte recruitment and inflammation, and loss of microvascular integrity leading to vascular leakage [4]. The Angiopoietin/Tie2 receptor system is a regulator of microvascular inflammation and vascular leakage and its importance in critical illness has previously been reviewed [5]. Angiopoietin-1 (Ang1) and Angiopoietin-2 (Ang2) are signaling molecules that bind to their specific endothelial tyrosine kinase receptor Tie2, which is constitutively expressed in the adult vasculature [6]. The Tie2 agonist Ang1 is produced by pericytes. In a quiescent state of the endothelium, binding of Ang1 to the Tie2 receptor leads to Tie2 phosphorylation which maintains endothelial cell integrity. The Tie2 antagonist Ang2 is a competitive antagonist of Ang1 produced by endothelial cells and is stored in Weibel-Palade bodies [7]. Upon stress and pro-inflammatory stimulation, Ang2 is released from endothelial cells into the circulation [8], where it binds to its receptor and reduces vascular integrity. Although the angiopoietins have long been considered to be the dynamic factors of the system, recent evidence suggests a reduction of Tie2 receptor expression levels on endothelial cells in animal models of critical illness [9]. Tie2 can be shed from the membrane, and soluble Tie2 (sTie2) and can act as a scavenger receptor for the angiopoietins.

It has been shown that the Ang/Tie2 system is deranged in septic patients [10,11] and after cardiac surgery [12,13]. Increased plasma levels of Ang2 have a prognostic value for mortality and morbidity in patients with chronic kidney disease [14,15]. In mice that developed AKI after sepsis, Ang2 and Tie2 messenger RNA levels in the kidney changed [16]. Therefore, we hypothesized that the Ang/Tie2 system is associated with the development of post-operative AKI reflected by changes in systemic plasma levels of Ang1, Ang2 and sTie2.

Materials and Methods

Patients

This observational study consisted of 541 patients, a subgroup of a larger randomized prospective multicenter clinical trial that investigated the effects of intraoperative cell salvage and leukocyte depletion on allogeneic blood exposure during cardiac surgery. The trial was registered at http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=244, under number ISRCTN58333401 and was approved by the Medical Ethical Committee of the University...
Medical Center Groningen, The Netherlands. Written informed consent was obtained from all patients included in the study. The main results of this study were previously published [17].

We identified 21 patients (4% of the total study population) who had a serum creatinine increase of at least 50% in the immediate post-operative period. According to the RIFLE criteria, this indicates AKI [18]. Urine output to assess AKI was not used in this study, as these data were not available for the whole patient group. Propensity score analysis, based on a forward stepwise logistic regression model was used to match the AKI patients in a one to one ratio with 21 patients that did not meet this criteria for AKI. As covariates, the baseline demographic variables were used, and in particular preoperative serum creatinine, preoperative hemoglobin level and estimated renal function as assessed by the Cockcroft-Gault formula. Procedure related variables were also entered into the model. These matched control pairs were created using a macro for SPSS (Version 18.0, IBM Chicago, Ill.), which compared the nearest propensity scores of the patients without AKI with the scores of the patients with AKI. The standardized difference between the groups were calculated to assess the imbalance of covariates (Table 1).

Procedures
Patients underwent coronary artery bypass grafting, valve replacement or combined procedures with use of cardiopulmonary bypass (CPB). The CPB circuit was primed with 1000 mL lactated Ringer’s solution and 500 mL hydroxyethylstarch 10% (Fresenius, Bad Homburg, Germany). All patients received standard anesthesia.

Blood sampling
Blood and urinary samples were obtained from each patient at 5 predefined moments: after induction of anesthesia, at the end of the surgery, after 3h in the intensive care unit, on the morning of the first post-operative (day 1) and at the morning of the second (day 2) post-operative day. Blood samples were centrifuged at 1000g for 10 minutes, and the plasma was stored in small portions at -80°C for analysis.

Measurements of plasma levels of soluble factors of the Ang/Tie2 system
Plasma levels of Ang1, Ang2 and sTie2 were measured with Quantikine ELISA kits (R&D Systems, Minneapolis, MN, USA), according to the manufacturer’s instructions.

Measurements of markers of renal injury
Serum creatinine was measured with an enzymatic creatinine assay (Roche Diagnostics GmbH, Mannheim, Germany). The urinary levels of Kidney Injury Molecule-1 (KIM-1) were measured with Quantikine ELISA kits (R&D Systems) according to the manufacturer’s instructions. Albumin levels in urine were determined by the bromcresol green method[19] and N-acetyl-β-D-glucosaminidase (NAG) levels were measured by means of a substrate assay [20].

Statistical analysis
Continuous data were analyzed using Student’s t-test or the Mann-Whitney U-test where appropriate. Categorical variables were analyzed using Fisher exact test. Two-way ANOVA with repeated measurements was used to compare serial data. Correlations between variables were analyzed by the Pearson correlation coefficient. All statistical analyses were performed using SPSS (Version 18.0, IBM Chicago, Ill). A P-value < 0.05 was considered significant.
Table 1. Patient demographics.

|                        | Overall (n = 541) | standardized differences overall vs AKI | AKI (n = 21) | standardized differences AKI vs control | Control (n = 21) | p-value (AKI vs control) |
|------------------------|-------------------|----------------------------------------|--------------|----------------------------------------|-----------------|-------------------------|
| Age (years)            | 66 ± 9.6          | 0.52                                   | 71 ± 8.4     | 0.47                                   | 68 ± 8.7        | 0.15                    |
| Height (cm)            | 173 ± 9           | -0.35                                  | 170 ± 10     | 0.10                                   | 169 ± 10        | 0.87                    |
| Weight (kg)            | 82 ± 13           | 0.75                                   | 83 ± 14      | 0.21                                   | 80 ± 14         | 0.46                    |
| Male (n (%))           | 400 (74)          | -0.13                                  | 14 (67)      | 0.25                                   | 11 (52)         | 0.53                    |
| EuroSCORE              | 4.4 ± 3.1         | 0.94                                   | 7.3 ± 4.3    | 0.44                                   | 5.7 ± 3.3       | 0.18                    |

Coexisting illness (%)

| Illness                | Overall | standardized differences overall vs AKI | AKI | standardized differences AKI vs control | Control | p-value (AKI vs control) |
|------------------------|---------|----------------------------------------|-----|----------------------------------------|---------|-------------------------|
| Myocardial infarction  | 24      | 0.00                                   | 24  | 0.10                                   | 20      | 1.00                    |
| PCI                    | 12      | 0.15                                   | 19  | 0.18                                   | 15      | 1.00                    |
| Hypertension           | 48      | 0.02                                   | 48  | -0.15                                  | 60      | 0.76                    |
| Stroke                 | 5       | 0.12                                   | 9   | 0.13                                   | 5       | 1.00                    |
| Atrial fibrillation    | 12      | 0.34                                   | 28  | 0.30                                   | 14      | 0.45                    |
| Diabetes               | 24      | 0.18                                   | 33  | 0.17                                   | 25      | 0.73                    |
| COPD                   | 13      | 0.05                                   | 14  | 0.00                                   | 15      | 1.00                    |

Medication (%)

| Medication            | Overall | standardized differences overall vs AKI | AKI | standardized differences AKI vs control | Control | p-value (AKI vs control) |
|-----------------------|---------|----------------------------------------|-----|----------------------------------------|---------|-------------------------|
| Aspirin <3 day        | 51      | -0.29                                  | 52  | 0.08                                   | 48      | 0.95                    |
| Beta blocker          | 69      | -0.03                                  | 67  | 0.00                                   | 67      | 1.00                    |
| Calcium-antagonist    | 28      | 0.17                                   | 38  | 0.00                                   | 38      | 1.00                    |
| ACE inhibitor         | 40      | 0.46                                   | 67  | 0.59                                   | 33      | 0.06                    |

Preoperative data

| Data                   | Overall | standardized differences overall vs AKI | AKI | standardized differences AKI vs control | Control | p-value (AKI vs control) |
|------------------------|---------|----------------------------------------|-----|----------------------------------------|---------|-------------------------|
| Hemoglobin (mmol/L)    | 7.6 ± 0.9 | -0.67                                 | 7.0 ± 0.9 | 0.00                                 | 7.0 ± 0.7 | 0.94                   |
| Platelets (x10⁹/L)     | 205 ± 57 | 0.09                                  | 210 ± 101 | 0.13                                 | 220 ± 54 | 0.72                   |
| Creatinine (mmol/L)    | 87 ± 27  | 0.11                                  | 90 ± 28  | 0.00                                  | 90 ± 26  | 0.98                   |
| Cockroft (mL/min)      | 89 ± 28  | -0.38                                 | 79 ± 26  | 0.00                                  | 78 ± 26  | 0.96                   |

Procedures

| Procedures             | Overall | standardized differences overall vs AKI | AKI | standardized differences AKI vs control | Control | p-value (AKI vs control) |
|------------------------|---------|----------------------------------------|-----|----------------------------------------|---------|-------------------------|
| CABG (n (%))           | 338 (62)| 10 (48)                                | 13  (62) | 13 (62)                                 |         |                         |
| Valve (n (%))          | 134 (25)| 5 (24)                                 | 6   (29) |                         |         |                         |
| CABG + valve (n (%))   | 69 (13) | 6 (29)                                 | 2   (9)  |                         |         |                         |

CPB management

| CPB management         | Overall | standardized differences overall vs AKI | AKI | standardized differences AKI vs control | Control | p-value (AKI vs control) |
|------------------------|---------|----------------------------------------|-----|----------------------------------------|---------|-------------------------|
| Aortic cross-clamp (min) | 66 ± 28 | 0.50                                   | 80 ± 30 | 0.24                                   | 73 ± 28  | 0.44                   |
| CPB time (min)         | 103 ± 42 | 0.45                                   | 122 ± 42 | 0.06                                   | 119 ± 53 | 0.83                   |
| Hemoglobin CPB (mmol/L)| 4.9 ± 0.74 | -0.68                                | 4.4 ± 0.60 | -0.16                                | 4.5 ± 0.63 | 0.63                   |

PCI: percutaneous coronary intervention, COPD: chronic obstructive pulmonary disease, CABG: coronary artery bypass grafting, CPB: cardiopulmonary bypass. Data are presented as mean ± SD or as a percentage where indicated. Standardized differences are shown between the whole patient group (overall) and the patients with acute kidney injury (AKI), and between AKI and a matched control group (control). P-values are given for AKI versus control group.

doi:10.1371/journal.pone.0136205.t001

Results

As per selection criterion, 21 patients with AKI had higher serum creatinine levels than the propensity-matched controls. Eleven patients had Risk of renal failure (mean post-operative serum creatinine level 149 ± 43 μmol/L), 9 patients had renal Injury (204 ± 54μmol/L) and 1
The plasma levels of Ang1, Ang2, and sTie2 changed over time in AKI and in control patients (Fig 1). Ang1 levels decreased over time in both groups from 8.5 ng/mL to 2.6 ng/mL (3-fold) (P<0.01). This decrease occurred at the end of the operation in both groups and did not return to baseline levels within 48h after surgery. Ang2 increased over time in both groups (control: from 3.0 ± 2.4 ng/mL to 6.7 ± 2.4 ng/mL; AKI: from 4.2 ± 3.0 ng/mL to 11.6 ± 7.6 ng/mL) (P = 0.013). This increase was 1.6-fold higher in patients with AKI at day 1 and 1.7-fold higher at day 2 after surgery. The plasma levels of Ang2 did not correlate with CPB time.

Plasma levels of sTie2 showed a drop of 1.6-fold at the end of the operation (from 19.5 to 11.3 ng/ml) and returned to baseline levels (18.3 ng/ml) within 48h after surgery. No interaction was found for both Ang1 (P = 0.583) and sTie2 (P = 0.679) between AKI patients and control patients.

The time course of the urinary markers albumin, KIM-1 and NAG is shown in Fig 2. Albumin levels did not change over time and we did not find an interaction between the groups. KIM-1 levels increased 3.2-fold (from 0.64 ± 0.67 ng/ml to 1.84 ± 1.75 ng/ml) in the AKI group, whereas in the control group the KIM-1 levels increased 2-fold (from 0.54 ± 0.42 ng/ml to 1.09 ± 1.14 ng/ml). KIM-1 levels were 2.4-fold higher in the AKI group compared to controls at day 1 and 1.9-fold higher at day 2. There was a difference between the groups over time (P = 0.05). NAG levels increased 4.2-fold (from 0.61 ± 0.88 U/l to 2.56 ± 1.62 U/l) in the AKI group, whereas in the control group the NAG levels increased 4.5-fold (from 0.35 ± 0.43 U/l to
Fig 1. Plasma levels of Angiopoietin-1, Angiopoietin-2 and soluble Tie2 in patients with and without acute kidney injury after cardiac surgery. A: Angiopoietin-1 (Ang1); B: Angiopoietin-2 (Ang2); C: Ang1/Ang2; D: soluble Tie2 (sTie2). AKI: acute kidney injury. Time points are before (pre-op) and at the end of
1.54± 1.33 U/l). NAG levels were 4.1-fold higher in the AKI group compared to control at day 1 ($P = 0.001$).

Because the plasma levels of Ang2 of the AKI and control patients showed a different post-operative time course, we next studied whether correlations were present between Ang2 plasma levels and markers of AKI (Fig 3). We found a positive correlation between the plasma levels of Ang2 and serum creatinine on the first post-operative day. We furthermore observed a positive correlation between the plasma levels of Ang2 and urinary NAG levels, while no correlation was observed between the plasma levels of Ang2 and urinary KIM-1 levels and between the plasma levels of Ang2 and urinary albumin concentrations.

Discussion

In this study we focused on changes in plasma levels of the Ang/Tie2 system in cardiac surgical patients who developed post-operative AKI. We demonstrated that higher systemic plasma levels of Ang2 were present in patients who develop AKI after cardiac surgery compared to matched controls. We found decreased systemic levels of Ang1 and sTie2 in both groups at the end of surgery, independent of the development of AKI. Plasma levels of sTie2 returned to baseline levels two days after surgery, whereas levels of Ang1 did not. Ang2 plasma levels correlated with the urinary AKI marker NAG.

Increased systemic levels of Ang2 have been described in patients after cardiac surgery [12,13] and have been associated with the duration of CPB [21]. We did not find such an association. We matched for aortic cross-clamp time and thus reduced outliers, which may affect the correlations that were found in two small scale studies [13,21]. The higher plasma levels of Ang2 in our patients with AKI may be explained by release of Ang2 from the Weibel-Palade bodies from the activated endothelium, rather than by a diminished excretion of Ang2. Although an inverse correlation between plasma Ang2 and glomerular filtration rate has been described [22,23]. It should also be noted that in insulin-dependent patients with diabetes type 2 and albuminuria, urine Ang2 levels increase while urine Ang1 levels decrease [24] suggesting that the higher levels of Ang2 in our AKI patients cannot be completely explained by a diminished excretion of Ang2. We did not find a correlation between the plasma levels of Ang2 and albuminuria. This has been found in chronic kidney disease [22], but may not be the case in the acute setting of our study. Plasma levels of Ang2 correlated with urinary NAG levels in our patients, which suggests a relation between systemic levels of Ang2 and AKI, but we did however not find a correlation with urinary KIM levels that could support such a relation.

Endothelial behavior in cardiac patients is controlled by multiple cytokines [25] vascular growths factors like the VEGF/VEGFR system and Ang/Tie2 system [12], hypoxia [26] and local blood flow [27]. However, in our previous study we found low levels in VEGF (about 50 ng/mL). It is therefore likely that Ang2 is mainly associated with apoptosis and vessel disintegration [7].

In healthy conditions, Ang1 binds to the Tie2 receptor, resulting in phosphorylation of the Tie2 receptor leading to reduced endothelial cell activation and reduced vascular leakage[5]. Ang2 is a competitive antagonist of Ang1. During inflammatory conditions, the pro inflammatory cytokine TNF-α, induces Ang2 release from endothelial cells [28]. Ang2 is then rapidly released from the Weibel-Palade bodies [29]. Ang2 sensitizes the endothelial cells to
Fig 2. Urinary levels of markers for renal injury in patients with and without acute kidney injury after cardiac surgery. A: Albumin; B: Kidney Injury Molecule-1 (KIM-1); C: N-acetyl-β-D-glucosaminidase (NAG). AKI: acute kidney injury. Time points are before (pre-op) and at the end of the operation (end-op), after 3 hours in the intensive care unit (3h ICU) and on the first and second post-operative day (day 1 and day 2). P-values are given for differences between the groups (#P_{group}) and differences in time (P_{time}), using two-way ANOVA with repeated measurements.

doi:10.1371/journal.pone.0136205.g002
inflammatory mediators [30]. Ang2 acts as an antagonist of Ang1 and binds to the Tie2 receptor with higher affinity than Ang1, leading to dephosphorylation of the Tie2 receptor. In our study, we found reduced levels of Ang1 and increased levels of Ang2. Given that endothelial activation occurs within 30min after the induction of hemorrhagic shock [31], that Ang2 is

Fig 3. Correlations between plasma Ang2 levels and urinary levels of markers renal injury on the first post-operative day in patients after cardiac surgery. A: serum creatinine; B: urine Kidney Injury Molecule-1 (KIM-1); C: urine Albumin; D: urine N-acetyl-β-D-glucosaminidase (NAG); Correlation (R) is given when significant. Statistics are analyzed using the Pearson correlation coefficient.

doi:10.1371/journal.pone.0136205.g003
rapidly released from endothelial cells, and that kidney injury cannot be measured at that time yet, it is likely that AKI is a consequence of endothelial dysfunction that could lead to vascular leakage.

In kidney biopsies of patients who died with AKI in the ICU mRNA levels of Ang1, Ang1/Ang2 ratio, and Tie2 were decreased immediate post-mortem [10] It is tempting to speculate that these changes also take place in kidneys of CPB patients who develop AKI. However, the functional consequences of this Ang1/Ang2 dysbalance on vascular inflammation and leakage in the kidney cannot be examined using soluble levels of angiopoietins and Tie2 in cardiac surgical patients. Based on the fast response of endothelial cells to release Ang2 in the blood in healthy volunteers injected with LPS [8], we expected an increase in Ang2 plasma levels at an early time point after cardiac surgery, but we found increased Ang2 plasma levels on the first post-operative day, and the Ang2 levels gradually increased more on the second post-operative day. Currently we do not know which organs contribute most to the increased Ang2 levels. It is likely that organs with a high vascular density play a crucial role. Our study suggests that destabilization of the Ang/Tie2 system in mature, non-remodeling vessels might be a new target to prevent AKI after cardiac surgery. Different pharmacological strategies to intervene in the Ang/Tie2 system have already been used in the past in animal models [32–34]. It would be worthwhile to use a rodent CPB model to compare circulatory markers with tissue markers and study local effects on Tie2 phosphorylation, endothelial inflammation, vascular leakage in the kidney and kidney function. Novel drug therapies that influence the Ang/Tie2 can be tested in these animal models. Taken together, influencing the Ang/Tie2 signaling pathway might be a therapeutic target for the prevention or treatment of AKI post CPB.

Our study has several limitations. First, from our overall cohort of 541 patients, we found only 21 patients (4%) who developed AKI. We selected the patients only on elevations of serum creatinine according to the RIFLE criteria, and did not use urine output criteria. These data were not available for the whole patient cohort as at the time of inclusion of the patients, electronic data management systems were not universally used. If we had applied the elevations of serum creatinine according to the AKIN criteria (that also take into account an absolute creatinine increase more than 26.2 μmol/l), an additional 29 patients, all in AKIN stage 1, would have met the criteria of AKI (9.3%). Using creatinine levels only, AKI incidence is underestimated [35]. Second, we cannot compare our patients with other patients in the ICU, because we have no complete dataset to assess APACHE or SOFA score. Third, we did not analyze the whole patient cohort, therefore propensity matching was necessary to find patients that could serve as non-AKI controls. Fourth, the absolute levels of urine albumin, KIM-1 and NAG were low, most likely because of the development of the relatively mild AKI. However, degradation of proteins in urine stored for longer periods cannot be excluded [36]. And finally, patients in the AKI group were well matched with the control group, except for the use of ACE inhibitors.

**Conclusions**

Cardiac surgery with the use of CPB leads to systemic changes in molecules of the Ang/Tie2 system, and these changes are more pronounced in patients that develop AKI. Ang2 levels increased more in patients who developed AKI after cardiac surgery, compared to matched controls and correlated with urine NAG levels. Animal studies aimed at restoring the Ang1/Ang2 balance as a tool to prevent AKI are warranted. These studies will extend our knowledge on therapies for patients with AKI after cardiac surgery.

**Acknowledgments**

We would like to thank Ans Hagenaars for valuable help in study management.
Author Contributions

Conceived and designed the experiments: JGZ AJdV MvM. Performed the experiments: RMJ. Analyzed the data: RMJ MvM. Wrote the paper: RMJ AJdV MvM. Included patients and collected patient material: JvK. Supervised the laboratory procedures: GM MvM. Performed statistics: AJdV. Critically revised the manuscript: JvK JGZ GM.

References

1. Loef BG, Epema AH, Navis G, Ebels T, Stegeman CA. Postoperative renal dysfunction and preoperative left ventricular dysfunction predispose patients to increased long-term mortality after coronary artery bypass graft surgery. Br J Anaesth. 2009; 102: 749–755. doi:10.1093/bja/aep088 PMID: 19411669

2. Reents W, Hilker M, Borgemann J, Albert M, Plotze K, Zacher M, et al. Acute kidney injury after on-pump or off-pump coronary artery bypass grafting in elderly patients. Ann Thorac Surg. 2014; 98: 9–15. doi:10.1016/j.athoracsur.2014.01.088 PMID: 24881861

3. Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH. Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med. 2014; 189: 1075–1081. doi:10.1164/rccm.201311-2097OC PMID: 24601781

4. Sutton TA. Alteration of microvascular permeability in acute kidney injury. Microvasc Res. 2009; 77: 4–7. doi:10.1016/j.mvr.2008.09.004 PMID: 18938184

5. van Meurs M, Kumpers P, Ligtenberg JJ, Meertens JH, Molema G, Zijlstra JG. Bench-to-bedside review: Angiopoietin signalling in critical illness—a future target? Crit Care. 2009; 13: 207. doi:10.1186/cc7153 PMID: 19435476

6. Wong AL, Haroon ZA, Werner S, Dewhirst MW, Greenberg CS, Peters KG. Tie2 expression and phosphorylation in angiogenic and quiescent adult tissues. Circ Res. 1997; 81: 567–574. PMID:9314838

7. Fiedler U, Augustin HG. Angiopoietins: a link between angiogenesis and inflammation. Trends Immunol. 2006; 27: 552–558. PMID:17045842

8. Kumpers P, van Meurs M, David S, Molema G, Bijzet J, Lukasz A, et al. Time course of angiopoietin-2 release during experimental human endotoxemia and sepsis. Crit Care. 2009; 13: R64. doi:10.1186/cc7866 PMID: 19416526

9. van Meurs M, Kurniati NF, Vom Hagen F, Jongman RM, Moser J, Zwiers PJ, et al. Shock-induced stress induces loss of microvascular endothelial Tie2 in the kidney which is not associated with reduced glomerular barrier function. Am J Physiol Renal Physiol. 2009; 297: F272–F281. doi:10.1152/ajprenal.00137.2009 PMID: 19515812

10. Aslan A, Jongman RM, Moser J, Stegeman CA, van Goor H, Diepstra A, et al. The renal angiopoietin/Tie-2 system in lethal human sepsis. Crit Care. 2014; 18: 423. doi:10.1186/cc13806 PMID: 24976393

11. Parikh SM. Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS. Virulence. 2013; 4: 517–524. doi:10.4161/viru.24906 PMID: 23652985

12. Jongman RM, Zijlstra JG, Kok WF, van Harten AE, Mariani MA, Moser J, et al. Off pump CABG surgery reduces systemic inflammation compared with on pump surgery but does not change systemic endothelial responses: a prospective randomized study. Shock. 2014.

13. Giuliano JS Jr, Lahni PM, Bigham MT, Manning PB, Nelson DP, Wong HR, et al. Plasma angiopoietin-2 levels increase in children following cardiopulmonary bypass. Intensive Care Med. 2008; 34: 1851–1857. doi:10.1007/s00134-008-1174-9 PMID: 18516587

14. Kumpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, et al. Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med. 2010; 36: 462–470. doi:10.1007/s00134-009-1726-7 PMID: 19956923

15. David S, John SG, Jefferies HJ, Sigrist MK, Kumpers P, Kielstein JT, et al. Angiopoietin-2 levels predict mortality in CKD patients. Nephrol Dial Transplant. 2012; 27: 1867–1872. doi:10.1093/ndt/gfr551 PMID: 21976741

16. Kurniati NF, van Meurs M, Vom Hagen F, Jongman RM, Moser J, Zwiers PJ, et al. Pleiotropic effects of angiopoietin-2 deficiency do not protect mice against endotoxin-induced acute kidney injury. Nephrol Dial Transplant. 2012.

17. Vermeijden WJ, van Klarenbosch J, Gu YJ, Mariani MA, Buhre WF, Scheeren TW, et al. Effects of Cell-Saving Devices and Filters on Transfusion in Cardiac Surgery: A Multicenter Randomized Study. Ann Thorac Surg. 2014.
18. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney Int. 2008; 73: 538–546. PMID: 18160961
19. Gustafsson JE, Uzqueda HR. Urinary albumin determination by the immediate bromcresol green method. Clin Chim Acta. 1978; 90: 241–248. PMID: 31993
20. Nauta FL, Bakker SJ, van Oeveren W, Navis G, van der Heide JJ, van Goor H, et al. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Am J Kidney Dis. 2011; 57: 733–743. doi:10.1053/ajkd.2010.12.022 PMID: 21458900
21. Ciajus C, Lukasz A, David S, Hertel B, Lichtinghagen R, Parikh SM, et al. Angiopoietin-2 is a potential mediator of endothelial barrier dysfunction following cardiopulmonary bypass. Cytokine. 2012.
22. Chang FC, Lai TS, Chiang CK, Chen YM, Wu MS, Chu TS, et al. Angiopoietin-2 is associated with albuminuria and microinflammation in chronic kidney disease. PLoS One. 2013; 8: e54668. doi:10.1371/journal.pone.0054668 PMID: 23469160
23. David S, Kumpers P, Lukasz A, Fliser D, Martens-Lobenhoffer J, Bode-Boger SM, et al. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease. Nephrol Dial Transplant. 2010; 25: 2571–2576. doi: 10.1093/ndt/gfq060 PMID: 20179005
24. Chen S, Li H, Zhang C, Li Z, Wang Q, Guo J, et al. Urinary angiopoietin-2 is associated with albuminuria in patients with type 2 diabetes mellitus. Int J Endocrinol. 2015; 2015: 163120. doi:10.1155/2015/163120 PMID: 25873946
25. Pober JS. Effects of tumour necrosis factor and related cytokines on vascular endothelial cells. Ciba Found Symp. 1987; 131: 170–184. PMID: 3300009
26. Nonami Y. The role of nitric oxide in cardiac surgery. Surg Today. 1997; 27: 583–592. PMID: 9306558
27. Li R, Zijlstra JG, Kamps JA, van Meurs M, Molema G. Abrupt Reflow Enhances Cytokine Induced Pro-Inflammatory Activation of Endothelial Cells During Simulated Shock and Resuscitation. Shock. 2014.
28. Kim I, Kim JH, Ryu YS, Liu M, Koh GY. Tumor necrosis factor-alpha upregulates angiopoietin-2 in human umbilical vein endothelial cells. Biochem Biophys Res Commun. 2000; 269: 361–365. PMID: 10708557
29. Fiedler U, Scharpfenecker M, Koidl S, Hegen A, Grunow V, Schmidt JM, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004; 103: 4150–4156. PMID: 14976056
30. Fiedler U, Reiss Y, Scharpfenecker M, Grunow V, Koidl S, Thurston G, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med. 2006; 12: 235–239. PMID: 16462802
31. van Meurs M, Wulftert FM, Knol AJ, De Haes A, Houwertjes M, Aarts LP, et al. Early organ-specific endothelial activation during hemorrhagic shock and resuscitation. Shock. 2008; 29: 291–299. PMID: 17704730
32. Kim DH, Jung YJ, Lee AS, Lee S, Kang KP, Lee TH, et al. COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury. Kidney Int. 2009; 76: 1180–1191. doi: 10.1038/ki.2009.387 PMID: 19812542
33. David S, Park JK, Meurs M, Zijlstra JG, Koenecce C, Schrimp C, et al. Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis. Cytokine. 2011; 55: 251–259. doi:10.1016/j.cyto.2011.04.008 PMID: 21531754
34. Stehle T, Thamm K, Kaufmann J, Schaeper U, Kirsch T, Hallier H, et al. Lung-Targeted RNA Interference Against Angiopoietin-2 Ameliorates Multiple Organ Dysfunction and Death in Sepsis. Crit Care Med. 2014.
35. Wlodzimirow KA, Abu-Hanna A, Slabbekoom M, Chamuleau RA, Schultz MJ, Bouman CS. A comparison of RIFLE with and without urine output criteria for acute kidney injury in critically ill patients. Crit Care. 2012; 16: R200. doi: 10.1186/cc11808 PMID: 23078781
36. Nauta FL, Bakker SJ, Lambers Heerspink H, de Zeeuw D, van Oeveren W, Bilo H, et al. Effect of frozen storage on urinary concentration of kidney damage markers. Am J Kidney Dis. 2012; 59: 586–589. doi: 10.1053/ajkd.2011.11.025 PMID: 22206741